Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data
| Autor: | Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María del Pilar Briceño-Casado |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Clinical outcome lcsh:R lcsh:Medicine lcsh:RS1-441 Antibodies Monoclonal Psoriasis treatment Real-world study Severity of Illness Index Etanercept lcsh:Pharmacy and materia medica Biological Therapy Retrospective study Long-term care Treatment Outcome Drug switching Humans Psoriasis Ustekinumab drug evaluation studies Retrospective Studies |
| Zdroj: | Farmacia Hospitalaria v.44 n.5 2020 SciELO España: Revistas Científicas Españolas de Ciencias de la Salud Instituto de Salud Carlos III (ISCIII) SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname Farmacia Hospitalaria, Vol 44, Iss 5, Pp 218-221 (2020) |
| Popis: | Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti-tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinumab in moderate-severe plaque psoriasis refractory to 2 anti-tumour necrosis factor α drugs.Retrospective descriptive study from January 2010 to March 2019. The study included patients with moderate-severe plaque psoriasis previously treated with at least 2 anti-tumour necrosis factor α biologic drugs. The effectiveness endpoints were Psoriasis Area and Severity Index 90 and 75 response rates at weeks 24, 48, 72, and 96. Safety was assessed using adverse effects and treatment withdrawal.A total of 36 patients were included (men, 61%). Ustekinumab was used after treatment with 2 anti-tumour necrosis factor α drugs in 88.9% of patients. The biologic drugs most frequently administered prior to ustekinumab were infliximab (94.4%) and etanercept (91.7%). It was observed that at least 66.7% of patients reached Psoriasis Area and Severity Index 90 at weeks 24, 48, 72, and 96. Adverse effects were recorded in 6 patients. There were no treatment withdrawals.Ustekinumab showed real long-term effectiveness and safety in moderate-severe plaque psoriasis with inadequate response to 2 previous anti- tumour necrosis factor α drugs.Objetivo: Ustekinumab se usa en psoriasis en placas moderada-grave con respuesta inadecuada a fármacos antifactor de necrosis tumoral α. Recientes estudios sostienen la escasez de resultados en vida real a largo plazo. El objetivo es evaluar la efectividad y seguridad de larga duración de ustekinumab en psoriasis en placas moderada-severa refractaria a dos fármacos antifactor de necrosis tumoral α.Método: Estudio descriptivo retrospectivo entre enero de 2010 y marzo de 2019. Se incluyeron pacientes con psoriasis en placas moderada-grave tratados previamente con al menos dos agentes biológicos antifactor de necrosis tumoral α. Las variables de efectividad fueron respuestas Psoriasis Area and Severity Index 90 y 75 a las 24, 48, 72 y 96 semanas. La seguridad fue valorada mediante reacciones adversas y suspensiones de tratamiento.Resultados: Se incluyeron 36 pacientes. El 61% fueron varones. Ustekinumab fue usado tras dos fármacos antifactor de necrosis tumoral α en el 88,9% de los pacientes. Los agentes biológicos previos más frecuentes fueron infliximab (94,4%) y etanercept (91,7%). Se observó que, al menos, el 66,7% de los pacientes alcanzaron Psoriasis Area and Severity Index 90 en las semanas 24, 48, 72 y 96. Se registraron reacciones adversas asociadas a ustekinumab en 6 pacientes. No hubo suspensiones. Conclusiones: Ustekinumab ha demostrado ser efectivo y seguro a largo plazo según resultados de vida real en psoriasis en placas moderada-severa tras respuesta inadecuada a dos fármacos antifactor de necrosis tumoral α. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|